20 May 2013
Keywords: arpida, initiates, major, cost-cutting, program, swiss, drug
Article | 08 December 2008
Swiss drug developer Arpida says it has begun a "significant" cost-cutting program to focus resources on its lead product iclaprim, ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
8 December 2008
© 2013 thepharmaletter.com